Boehringer adds to NASH pipeline with $870 million deal
Germany’s Boehringer Ingelheim and South Korean firm Yuhan Corp (000100: KS) today announced a collaboration and license agreement for the development of a first-in-class dual agonist for the treatment of non-alcoholic C (NASH) and related liver diseases that combines GLP-1 and FGF21 activity in one molecule.
The collaboration brings together Yuhan’s expertise in FGF21 biology, obesity and NASH with family-owned Boehringer Ingelheim’s pharmaceutical expertise and commitment to bringing innovative medicines to patients with cardiometabolic diseases.
News of the deal saw Yuhan’s shares close up 2.86% at 251,500 won today, having hit an intraday high of 267,500 won, despite the fact that research efforts on NASH candidates have seen a string of disappointments so far.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze